


CLAIMS

1. A crystalline solid of a compound having the structure:



~~or stereoisomers, tautomers, or solvates thereof~~ wherein the crystalline solid is characterized by an X-ray powder diffraction pattern comprising peaks, expressed in values of degrees 2Θ , at about 8.07; about 10.81; about 14.68; and about 22.07 ± 0.2 .

2. The crystalline solid of claim 1, wherein the crystalline solid of the compound ~~has~~ is characterized by an X-ray powder diffraction pattern ~~with characteristic~~ comprising peaks, expressed in values of degrees 2Θ , at about 8.07; about 10.81; about 14.68; about 16.69; about 17.34; and about 22.07 ± 0.2 .


~~3. The crystalline solid of claim 1, wherein the crystalline solid of the compound has an X-ray powder diffraction pattern with characteristic peaks expressed in values of degrees 2Θ at about 8.07; about 10.81; about 14.68; about 16.69; about 17.34; and about 22.07 ± 0.2 .~~

- ~~34. The crystalline solid of claim 1, wherein the crystalline solid of the compound is characterized by~~ has an X-ray powder diffraction pattern ~~with characteristic~~ comprising peaks, expressed in values of degrees 2Θ , at about 8.07; about 10.81; about 12.00; about 12.37; about 13.79; about 14.68; about 15.39; about 16.19; about 16.69; about 17.34; about 18.89; about 20.26; about 21.15; about 21.30; about 21.77; about 22.07; about 22.84; about 23.49; about 24.40; about 24.90; about 25.34; about 25.75; about 26.12; about 26.54; about 27.16; about 27.48; about 28.06; about 28.76; about 29.04; about 29.26; and about 29.59 ± 0.2 .

- ~~54. The crystalline solid of claim 1, wherein the crystalline solid is characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 1.~~

65. A pharmaceutical composition comprising (i) a therapeutically effective amount of at least one ~~a~~ crystalline solid according to claim 1 or a stereoisomer, tautomer, or solvate thereof; (ii) ~~in combination with a pharmaceutically acceptable carrier, diluent or excipient.~~

7. ~~The pharmaceutical composition of claim 6, wherein the pharmaceutically acceptable excipient comprises~~ a compound having the structure:



wherein the crystalline solid is characterized by an X-ray powder diffraction pattern comprising peaks, expressed in values of degrees 2 Θ , at about 8.07; about 10.81; about 14.68; and about 22.07 $\pm$ 0.2; and (ii)

- (a) a microcrystalline cellulose in the amount of 20.0 to 40.0 w/w% by total weight of composition;
- (b) citric acid ranging in the amount of 5.0 to 20.0 w/w% by total weight of composition;
- (c) sodium bicarbonate in the amount of 5.0 to 25.0 w/w% by total weight of composition;
- (d) sodium lauryl sulfate in the amount of 1.0 to 10.0 w/w% by total weight of composition;
- (e) fumed silica in the amount of 0.1 to 5.0 w/w% by total weight of composition; and
- (f) magnesium stearate in the amount of 0.1 to 5.0 w/w% by total weight of composition.

86. The pharmaceutical composition of claim ~~7~~5, wherein:

(a) the pharmaceutically acceptable excipient comprises:

- ~~(a) a microcrystalline cellulose~~ is present in the amount of 25.0 to 35.0 w/w% by total weight of composition;
- ~~(b) the citric acid ranging~~ is present in the amount of ~~15.0 to 25.0~~5.0 to 20.0 w/w% by total weight of composition;

- (c) the sodium bicarbonate is present in the amount of 10.0 to 20.0 w/w% by total weight of composition;
- (d) the sodium lauryl sulfate is present in the amount of 3.0 to 8.0 w/w% by total weight of composition;
- (e) the fumed silica is present in the amount of 0.1 to 2.0 w/w% by total weight of composition; and
- (f) the magnesium stearate is present in the amount of 0.1 to 2.0 w/w% by total weight of composition.

97. The pharmaceutical composition of claim 86, wherein ~~wherein the pharmaceutically acceptable excipient comprises:~~

- (a) ~~at~~ the microcrystalline cellulose is present in the amount of 30.0 to 35.0 w/w% by total weight of composition;
- (b) the citric acid ~~range~~ is present in the amount of 10.0 to 15.0 w/w% by total weight of composition;
- (c) the sodium bicarbonate is present in the amount of 13.0 to 17.0 w/w% by total weight of composition;
- (d) the sodium lauryl sulfate is present in the amount of 3.0 to 8.0 w/w% by total weight of composition;
- (e) the fumed silica is present in the amount of 0.5 to 1.5 w/w% by total weight of composition; and
- (f) the magnesium stearate is present in the amount of 0.5 to 1.5 w/w% by total weight of composition.

10. ~~— A method for attenuating or inhibiting the activity of Mnk in at least one cell overexpressing Mnk, comprising contacting the at least one cell with a compound according to claim 1 or a stereoisomer, tautomer or solvate thereof.~~

11. ~~— The method of claim 10, wherein the at least one cell is a colon cancer cell, a gastric cancer cell, a thyroid cancer cell, a lung cancer cell, a leukemia cell, a B-cell lymphoma, a T-cell lymphoma, a hairy cell lymphoma, Hodgkin's lymphoma cell, non-Hodgkin's lymphoma cell, Burkitt's lymphoma cell, a pancreatic cancer cell, a melanoma cell, a multiple melanoma cell, a~~

~~brain cancer cell, a CNS cancer cell, a renal cancer cell, a prostate cancer cell, an ovarian cancer cell, or a breast cancer cell.~~

~~12. — A method for treating an Mnk dependent condition in a mammal in need thereof, comprising administering to the mammal (i) a therapeutically effective amount of at least one compound according to claim 1 or a stereoisomer, tautomer, or solvate thereof, or (ii) a pharmaceutical composition of claim 4.~~

~~13. — The method of claim 12, wherein the Mnk dependent condition is colorectal cancer, gastric cancer, thyroid cancer, lung cancer, leukemia, B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, pancreatic cancer, melanoma, multiple melanoma, brain cancer, CNS cancer, renal cancer, prostate cancer, ovarian cancer or breast cancer.~~

~~14. — The method of claim 13, wherein the condition is B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, pancreatic cancer, melanoma, multiple melanoma, brain cancer, renal cancer, prostate cancer, ovarian cancer, and breast cancer.~~

~~15. — The method of claim 14, wherein the condition is B-cell lymphoma, breast cancer, lung cancer, colorectal cancer, and prostate cancer.~~